| Literature DB >> 26190983 |
Mikhail Votinov1, Juergen Pripfl2, Christian Windischberger3, Ewald Moser3, Uta Sailer4, Claus Lamm2.
Abstract
Whether the opioid system plays a role in the ability to flexibly adapt behavior is still unclear. We used fMRI to investigate the effect of a nucleotide tandem repeat (68-bp VNTR) functional polymorphism of the prodynorphin (PDYN) gene on cerebral activation during a reversal learning task in which participants had to flexibly adapt stimulus-response associations. Past studies suggested that alleles with 3 or 4 repeats (HH genotype) of this polymorphism are associated with higher levels of dynorphin peptides than alleles with 1 or 2 repeats (LL genotype). On the behavioral level, the HH group made more perseverative errors than the LL group. On the neural level, the HH group demonstrated less engagement of left orbitofrontal cortex (lOFC) and cortico-striatal circuitry, and lower effective connectivity of lOFC with anterior midcingulate cortex and anterior insula/ventrolateral prefrontal cortex during reversal learning and processing negative feedback. This points to a lower ability of the HH genotype to monitor or adapt to changes in reward contingencies. These findings provide first evidence that dynorphins may contribute to individual differences in reversal learning, and that considering the opioid system may shed new light on the neurochemical correlates of decision-making and behavioral regulation.Entities:
Keywords: functional MRI; genetics; opioid system; prodynorphin; reversal learning
Year: 2015 PMID: 26190983 PMCID: PMC4490246 DOI: 10.3389/fnbeh.2015.00172
Source DB: PubMed Journal: Front Behav Neurosci ISSN: 1662-5153 Impact factor: 3.558
Demographic table.
| LL | 22 | 10/12 | 23.6 ± 1.4 |
| HH | 21 | 10/11 | 23.04 ± 0.8 |
Consumption of alcohol, tobacco, coffee, and energy drinks.
| LL | 22 | 0.68 ± 0.21 | 1.22 ± 0.16 | 1.95 ± 0.23 | 0.59 ± 0.12 |
| HH | 21 | 0.61 ± 0.21 | 1.19 ± 0.16 | 1.66 ± 0.23 | 0.52 ± 0.13 |
All p > 0.38.
Figure 1Schematic illustration of one trial of the probabilistic reversal task performed by subjects in the MRI scanner (left) and part of a trial sequence with different types of errors (right).
Figure 2Whole brain activation of all 43 participants for contrast Final Errors vs. Correct Responses (threshold < 0.05 FWE corrected at voxel level). The clusters in left/right anterior insula/ventrolateral PFC (circled in left panel), left/right lateral OFC (middle panel) and aMCC (right panel) were used for the ROI analyses (see Methods).
Behavioral results.
| Number of perseverative errors | LL 21.68 ± 1.6 | 0.03 | 0.11 | 0.59 |
| HH 27.24 ± 1.6 | ||||
| Number of spontaneous errors | LL 4.1 ± 1.1 | 0.35 | 0.021 | 0.15 |
| HH 5.6 ± 1.2 | ||||
| Response latency following misleading errors | LL 515.44 ± 20.4 | 0.68 | 0.004 | 0.07 |
| HH 503.39 ± 20.8 | ||||
| Response latency following correct responses | LL 491.83 ± 18.5 | 0.76 | 0.002 | 0.06 |
| HH 500.0 ± 19 | ||||
| Response latency following final reversal errors | LL 511.70 ± 25 | 0.72 | 0.003 | 0.06 |
| HH 498.86 ± 25.6 |
Results for BIS/BAS and BIS11 scale.
| LL | 3.01 ± 0.12 | 3.12 ± 0.09 | 3.11 ± 0.1 | 3.41 ± 0.09 | 16.4 ± 0.6 | 23.5 ± 0.8 | 22.18 ± 1 |
| HH | 2.88 ± 0.12 | 3.03 ± 0.1 | 2.95 ± 0.1 | 3.30 ± 0.09 | 16.5 ± 0.6 | 23.9 ± 0.8 | 23.8 ± 1 |
All p > 0.26.
List of clusters with significant activation for the contrast Final Errors vs. Correct Responses (thresholded at < 0.05, FWE corrected at voxel level) of all 43 participants.
| aInsula/Ventrolateral prefrontal cortex | R | 5388 | 13.21 | 34 | 24 | 0 | <0.0001 |
| Mid-cingulate cortex | s.c. | 12.27 | 9 | 23 | 43 | <0.0001 | |
| Mid-cingulate cortex | s.c. | 12.17 | 4 | 21 | 38 | <0.0001 | |
| perigenual anterior cingulate cortex | s.c. | 9.09 | 8 | 28 | 24 | <0.0001 | |
| Medial frontal gyrus | s.c. | 11.56 | 2 | 15 | 48 | <0.0001 | |
| Superior frontal gyrus | R | s.c. | 10.45 | 10 | 9 | 58 | <0.0001 |
| Dorsolateral prefrontal cortex | R | s.c. | 10.08 | 39 | 26 | 34 | <0.0001 |
| Lateral orbitofrontal cortex | R | s.c. | 8.77 | 32 | 51 | 10 | <0.0001 |
| Lateral orbitofrontal cortex | R | s.c. | 7.48 | 18 | 54 | −14 | <0.0001 |
| aInsula/Ventrolateral prefrontal cortex | L | 471 | 12.03 | −30 | 24 | 0 | <0.0001 |
| s.c | 10 | −40 | 15 | −5 | <0.0001 | ||
| Inferior parietal lobule | R | 1282 | 11.8 | 33 | −48 | 43 | <0.0001 |
| s.c. | 9.81 | 51 | −48 | 52 | <0.0001 | ||
| Inferior parietal lobule | L | 484 | 9.57 | −34 | −45 | 38 | <0.0001 |
| s.c. | 7.99 | −43 | −40 | 43 | <0.0001 | ||
| SMA | L | 185 | 8.4 | −25 | −3 | 52 | <0.0001 |
| Precuneus | R | 343 | 7.9 | 10 | −72 | 53 | <0.0001 |
| L | s.c. | 7.2 | −4 | −74 | 43 | <0.0001 | |
| Lateral orbitofrontal cortex | L | 232 | 7.6 | −33 | 58 | 5 | <0.0001 |
| L | s.c | 7.0 | −28 | 48 | 14 | <0.0001 | |
| Middle temporal gyrus | R | 114 | 7.7 | 50 | −28 | −10 | <0.0001 |
| Thalamus | R | 76 | 7.38 | 10 | −9 | 10 | <0.0001 |
| s.c. | 6.93 | 9 | −20 | 10 | <0.0001 | ||
| Striatum | R | 32 | 6.74 | 12 | 4 | 5 | <0.0001 |
| Lateral orbitofrontal cortex | L | 16 | 6.53 | −16 | 46 | −19 | <0.0001 |
| Midbrain | 6 | 6.2 | 9 | −24 | −10 | 0.003 | |
| Thalamus | L | 7 | 6.16 | −10 | −15 | 10 | 0.002 |
L/R, left/right in the brain; s.c., sub-cluster; SMA, Supplementary Motor area.
Figure 3BOLD signal (Parameter Estimates ± SEM) from all regions of interests in different (68-bp VNTR) prodynorphin promoter polymorphism genotypes (LL- and HH-alleles). (A) Final Errors vs. Correct Responses contrast. The HH (“high level pDYN expression”) group shows significantly lower activation in the left lateral OFC compared to the LL (“low level pDYN expression”) group; (B) All Errors vs. All Correct Responses. The HH group shows lower activation in the left ventral striatum, left caudate, and left lateral OFC compared to the LL group (*p < 0.05).
Figure 4BOLD signal (Parameter Estimates ± SEM) from all regions of interests in different (68-bp VNTR) prodynorphin promoter polymorphism genotypes (LL- and HH-alleles) for CR (Correct Response vs. Baseline), OE (Other Errors vs. Baseline), and FE (Final Errors vs. Baseline) in: (A) bilateral OFC; (B) bilateral aInsula/VMPFC; (C) aMCC; (D) Caudate (green), Ventral Striatum (red) and Putamen (blue). *Represents significant difference (p < 0.05), only for the contrast where was significant main effect of genotype on ROI activations.